**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 83518

**Manuscript Type:** REVIEW

**Classification of osteogenesis imperfecta: Importance for prophylaxis and genetic counseling**

Panzaru *et al*. Importance of OI classification

Monica-Cristina Panzaru, Andreea Florea, Lavinia Caba, Eusebiu Vlad Gorduza

**Monica-Cristina Panzaru, Lavinia Caba, Eusebiu Vlad Gorduza,** Department of Medical Genetics, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700115, Romania

**Andreea Florea,** Department of Medical Genetics - Medical Genetics resident, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700115, Romania

**Author contributions:** Panzaru MC, Caba L wrote the manuscript draft; Florea A performed the literature research; Panzaru MC and Gorduza EV wrote the review, and Gorduza EV supervised the manuscript.

**Corresponding author: Andreea Florea, MD, Doctor,** Department of Medical Genetics - Medical Genetics resident, “Grigore T. Popa” University of Medicine and Pharmacy, 16 University Street, Iasi 700115, Romania. andreeaflorea97@gmail.com

**Received:** January 28, 2023

**Revised:** March 18, 2023

**Accepted:** March 27, 2023

**Published online:** April 26, 2023

**Abstract**

Osteogenesis imperfecta (OI) is a genetically heterogeneous monogenic disease characterized by decreased bone mass, bone fragility, and recurrent fractures. The phenotypic spectrum varies considerably ranging from prenatal fractures with lethal outcomes to mild forms with few fractures and normal stature. The basic mechanism is a collagen-related defect, not only in synthesis but also in folding, processing, bone mineralization, or osteoblast function. In recent years, great progress has been made in identifying new genes and molecular mechanisms underlying OI. In this context, the classification of OI has been revised several times and different types are used. The Sillence classification, based on clinical and radiological characteristics, is currently used as a grading of clinical severity. Based on the metabolic pathway, the functional classification allows identifying regulatory elements and targeting specific therapeutic approaches. Genetic classification has the advantage of identifying the inheritance pattern, an essential element for genetic counseling and prophylaxis. Although genotype-phenotype correlations may sometimes be challenging, genetic diagnosis allows a personalized management strategy, accurate family planning, and pregnancy management decisions including options for mode of delivery, or early antenatal OI treatment. Future research on molecular pathways and pathogenic variants involved could lead to the development of genotype-based therapeutic approaches. This narrative review summarizes our current understanding of genes, molecular mechanisms involved in OI, classifications, and their utility in prophylaxis.

**Key Words:** Osteogenesis imperfecta; Heterogeneity; Classification; Molecular mechanism; Genetic counseling; Prophylaxis

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Panzaru MC, Florea A, Caba L, Gorduza EV. Classification of osteogenesis imperfecta: Importance for prophylaxis and genetic counseling. *World J Clin Cases* 2023; 11(12): 2604-2620

**URL:** https://www.wjgnet.com/2307-8960/full/v11/i12/2604.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v11.i12.2604

**Core Tip:** Osteogenesis imperfecta (OI) is a genetically heterogeneous systemic collagenous disorder with high phenotypic variability. Recent discoveries of new genes and molecular mechanisms underlying the disease have led to revisions of classical classification. Identifying the causative gene and molecular mechanisms allows a personalized management strategy, accurate family planning, and pregnancy management decisions including options for mode of delivery, or early antenatal OI treatment.

**INTRODUCTION**

Osteogenesis imperfecta (OI) is a rare monogenic disorder with an incidence estimated at about 1 per 10000 individuals[1]. It is a genetically and clinically heterogeneous disease characterized by decreased bone mass and bone fragility. This generates susceptibility to fractures with minimal or no trauma, vertebral compressions, variable skeletal deformities, and growth deficiency. Bone tissue is characterized by alterations of trabecular architecture, thin cortex, high bone turnover, and hypermineralized matrix. Patients with OI have a broad phenotypic spectrum ranging from prenatal fractures and pre and perinatal lethal outcome to mild forms with few fractures and normal stature. This phenotypic variability is only partially explained by the type of mutation or causative gene. Patients with the same pathogenic variant may present variable degrees of phenotype expression. The basic mechanism is a collagen-related defect, not only in structure or production, but also in folding, posttranslational processing, bone mineralization or osteoblast differentiation[2]. The disorder is a systemic collagen disorder and it also has extra-skeletal manifestations like blue-gray sclera, dentinogenesis imperfecta, conductive or sensory hearing loss, ligamentous laxity, muscle weakness, respiratory impairment, increased fragility of vessels, and cardiac valve abnormalities[1,3-5].

**COLLAGEN SYNTHESIS**

Collagen is a major component of the extracellular matrix, with essential roles in mechanical resistance and regulation of several signaling pathways. Type I collagen is a crucial skin, bone, tendons, lungs, heart, and blood vessels constituent. This collagen is a heterotrimer synthesized in a precursor form, procollagen, containing two proα1(I) and one proα2(I) chains. The procollagen has a rod-like central triple-helical domain with globular extensions at the N- and C- ends. The helical core contains repeating Gly-Xaa-Yaa tripeptides, where X is often proline and Y hydroxyproline. Type I procollagen synthesis is a complex process, involving numerous phases and many proteins necessary for post-translational modifications, folding, transport, and secretion. The proα1(I) and proα2(I) polypeptide chains, encoded by the *COL1A1* and *COL1A2* genes, are translated in the rough endoplasmic reticulum (ER). The post-translational modifications include 4‑hydroxylation of most prolines in the Yaa position – essential for triple helical stability. The complex formed by P3H1 – CRTAP – PPIB and the FKBP10 protein have an important role in triple helix formation. Serpin H1 is involved in the stabilization of the triple helix and transport to the Golgi apparatus. The terminal procollagen extensions are cleaved by specific proteases: Disintegrin, metalloproteinase with thrombospondin motifs 2 (ADAMTS2) and bone morphogenetic protein 1 (BMP1). Three specific regions, relevant to the interaction of collagen with other collagen molecules or extracellular matrix proteins, were identified along the α1‑chain - major ligand-binding regions (MLBRs), which are very important for matrix quality[6-9]. Pathogenic variants in gene-encoding key players in these processes lead to collagen defects and OI phenotype.

**CLASSIFICATION**

Lately, OI classification has been the subject of extensive debates and has been revised several times. In 1979, Sillence proposed a classification based on clinical/radiological characteristics and mode of inheritance: OI type I - autosomal dominant (AD) with blue sclerae, OI type II - perinatal lethal form with radiographically broad, crumpled femora and beaded ribs, OI type III - progressively deforming, and OI type IV – dominant with normal sclerae[10] (Figure 1). This classification included only patients with defects in the primary structure of collagen. The discovery of pathogenic variants in new genes with clinical overlap with previous types has caused many debates. In 2014, Van Dijk and Sillence suggested the addition of OI type V – a form with calcification in the intraosseous membranes[11]. The revised nosology and classification of genetic skeletal disorders recognizes these five clinical types (but Arabic numerals are used), with subclasses based on inheritance patterns and genes involved[12]. Some types (*e.g.* 3 or 4) have many genes and different inheritance (dominant/ recessive) resulting in challenges for genetic counseling. An alternative functional classification based on the metabolic mechanism was also proposed: Group A - defects in collagen synthesis, structure, or processing, group B - defects in collagen modification, group C - collagen folding and cross-linking defects, group D - compromised bone mineralization, and group E - defects in osteoblast development with collagen insufficiency[8,13]. The Online Mendelian Inheritance in Man database uses a mixed-genetic classification, with types I–IV according to the Sillence classification and pathogenic variants in *COL1A1* or *COL1A2*, and the new gene-classified type[1] (Table 1). The advantages of genetic classification are the identification of the inheritance pattern for counseling, prophylaxis, and the possibility of grouping for etiology-based therapies research.

**GENES AND PROTEINS INVOLVED IN OI**

***COL1A1 and COL1A2***

Over 85% of OI cases are associated with pathogenic variants in *COL1A1* and *COL1A2* genes, which lead to quantitative or qualitative alterations of collagen. These mutations generate OI types I - IV. Pathogenic variants (mostly nonsense mutations) lead to haploinsufficiency and reduce the amount of normal collagen, thus generating a milder phenotype. In contrast, pathogenic variants leading to structural collagen defects cause a more severe phenotype. The most common mutations are single-nucleotide variants resulting in the substitution of a glycine residue. Substitutions in gene regions that encode branched-chain or charged amino acids interfere with triple helix folding and are associated with severe clinical consequences. Substitutions on the α1(I) chain have a more severe/Lethal outcome than those in α2(I). The nature of the substituting amino acid, the chain in which it is located, and its position along the chain influence the phenotype. Pathogenic variants in the 3ʹ or 5ʹ splice sites that produce exon skipping do not affect the Gly-Xaa-Yaa triplet pattern but may cause local looping out of chains[1,2]. Pathogenic variants in the C-terminal propeptide, which is cleaved from the mature collagen, impair chain association or delay the incorporation into the collagen trimer[14]. Deletions or duplications of the codons for one or two Gly-Xaa-Yaa triplets shift the chain alignment without interrupting the sequence and produce severe or lethal phenotypes[15]. Due to the direction of the zipper-like folding of the chains, pathogenic variants in the N-terminal region have minimal consequences, whereas those in the C-terminal region cause moderate to lethal outcomes. Substitutions in MLBR3 regions impair extracellular matrix organization and usually have lethal consequences. In the α2(I) chain, severe pathogenic variants are gathered in clusters that are correlated with the proteoglycan binding site on collagen fibrils[16-19] .

***IFITM5***

Interferon-induced transmembrane protein 5 (IFITM5), also known as bone-restricted IFITM-like, is a short transmembrane protein expressed specifically in osteoblasts and attached to the cell membrane by palmitoylation of cysteines 50 and 5, with a regulatory role in mineralization. IFITM5 plays a crucial role in the regulation of *SERPINF1* expression and the resultant production of the protein pigment epithelium-derived factor (PEDF). Different pathogenic variants in *IFITM5* gene lead to a distinct OI phenotype, named OI V. A heterozygous gain of (new) function variant in the 5' untranslated region (c.-14C>T) is associated with a moderate type of OI with distinctive radiographic findings. This pathogenic variant creates a new start codon, resulting in the elongation of the cytoplasmic N- terminus of IFITM5 protein by five amino acids and inducing increased bone for­mation[2,20,21]. The characteristic radiographic findings include hyperplastic callus formation, calcification of the interosseous membrane of the forearm, and hyperdense metaphyseal band. Some patients may present radial head dislocation. Histologic examination of bone under polarized light reveals a “*mesh-like pattern*” of irregularly arranged lamellar deposition[22]. Heterozygous missense variants lead to substitution of the serine at position 40 (c.119C>T and c.119C>G), impairment of the palmitoylation process, and are associated with a more severe phenotype. Patients present prenatal fractures or shortening/ bowing of long bones, a severe deforming course, and a fish-scale lamellar pattern at the bone examination under polarized light. Patients do not show radial head dislocation or signs from the radiographic triad. Lim *et al*[23] reported a case of gonadal mosaicism in the unaffected mother[24]. Bisphosphonates (BPs) are more effective in patients with c.119C>T variant than in cases with other variants[25].

***SERPINF1***

PEDF, encoded by *SERPINF1* gene, is aubiquitously expressed protein, with anti-angiogenic, anti-tumorigenic, and anti-metastatic properties. The binding of PEDF to type I collagen is essential for anti-angiogenic properties. PEDF induces the expression of osteoprotegerin which interacts with the receptor activator of nuclear factor-κβ ligand (RANKL) pathway and regulates the activity of osteoclasts. Kang *et al*[26] suggest that antagonism between PEDF and TGF-β pathways controls osteogenesis and bone vascularization[8,27]. Patients with biallelic pathogenic variants in *SERPINF1* have postnatal fractures, progressive skeletal deformity, vertebral compressions, and a fish-scale pattern at bone examination under polarized light (similar to patients with loss of function mutation in *IFITM5*). These mutations produce OI type VI. The RANKL-antibody is a potential therapeutic agent for this form of OI[1,4,28].

***CRTAP, P3H1 and PPIB***

Cartilage-associated protein (CRTAP) forms a complex with prolyl-3-hydroxylase 1 (P3H1) and peptidyl-prolyl-cis-transisomerase B (PPIB). This complex is involved in 3-hydroxylation of specific proline residues. Chang *et al*[29] showed that CRTAP and P3H1 are mutually stabilized in the collagen prolyl 3-hydroxylation complex. Biallelic pathogenic variants in *CRTAP* or *P3H1* genes lead to a marked decrease in proline hydroxylation and subsequently to a delay in collagen folding and are associated with a severe/lethal form of OI. Patients have neonatal fractures, rhizomelia, and undertubulation of the long bones[4,13,30-31]. Biallelic pathogenic variants in *PPIB* gene are associated with a low percentage of 3-hydroxylated proline at position 986, but higher than in *CRTAP* or *P3H1* genes mutations. The phenotype overlaps with that caused by *CRTAP* or *P3H1* genes mutation, with the exception of rhizomelia[32,33]. *CRTAP* genes mutations determine OI type VII, *P3H1* genes mutations determine OI type VIII, while *PPIB* genes mutations determine OI type IX.

***SERPINH1***

Serpin H1 is a collagen-specific chaperone, that localizes in the ER and is encoded by *SERPINH1* gene. Serpin H1 binds to arginine-rich sequences of triple helical collagen and stabilizes it by preventing unfolding and aggregate formation. Also, serpin H1 participates in the shuttling of correctly folded collagen into the Golgi apparatus. Homozygous or compound heterozygous pathogenic variants in *SERPINH1* gene lead to misfolding, intracellular aggregation, and delayed collagen secretion and are associated with a moderate to severe form of OI – OI type X[34-36].

***FKBP10***

Serpin H1 interacts with peptidyl-prolyl cis-trans isomerase FKBP10, another collagen chaperone, which provides mutual stability and allows for a synergistic effect during collagen folding. FKBP10 is also required for the activity of lysyl hydroxylase 2 (LH2, encoded by *PLOD2* gene). Hydroxylation of the collagen telopeptide lysyl residues is essential in cross-linking. Recessive pathogenic variants in *FKBP10* gene are associated with a wide clinical spectrum which includes a progressive deforming form of OI (OI type XI), Bruck syndrome, and Kuskokwim syndrome. Bruck syndrome is characterized by congenital contractures with pterygia, early onset of fractures, short stature, limb deformity, and progressive scoliosis. Bruck syndrome 2 presents a similar phenotype, but it is generated by a biallelic pathogenic variant in *PLOD2* gene. Kuskokwim syndrome is a congenital contracture disorder with mild skeletal anomalies, occurring in Yup’ik Eskimos in Alaska. Bisphosphonate therapy reduces the fracture rate and pain but has no effect on joint abnormalities[4,37-39].

***SP7***

*SP7* gene encodes transcription factor SP7, a key regulator of osteoblast differentiation and subsequently of osteocyte formation. Recessive pathogenic variants in *SP7* are associated with increased bone porosity, recurrent fractures, skeletal deformities, delayed teeth eruption and hearing loss. This particular phenotype is characteristic to OI type XII. Recently, heterozygous (dominant) missense variants affecting a highly conserved zinc finger domain have been reported in cases with bone fragility, high bone turnover, and patchy sclerosis[40-43].

***BMP1***

The major function of bone morphogenetic protein 1 (BMP1) involves procollagen I C‐terminal propeptide processing, crucial for fibril formation. Other roles are activation of lysyl oxidases (involved in cross-linking), processing of small leucine-rich proteoglycans (*e.g.* decorin - important for collagen fibrillogenesis) and dentin matrix protein 1 involved in bone mineralization, and activation of TGFβ1, a key signaling molecule for bone remodeling. Patients with homozygous or compound heterozygous pathogenic variants in *BMP1* gene present a variable phenotype ranging from mild to severe progressive deforming OI (OI type XIII). Individuals with *BMP1* pathogenic variants with residual activity of the protein have a milder phenotype than cases with null pathogenic variants. In the majority of cases, increased bone mineral density (BMD) has been noticed. In this context, the indication, dose, and duration of antiresorptive therapy are questionable due to concerns about increasing bone stiffness leading to fracture[2,44-47].

***TMEM38B***

*TMEM38B* gene encodes TRimeric Intracellular Cation channel type B (TRIC-B), specific for potassium, also known as transmembrane protein 38 (TMEM 38B). TMEM 38B is involved in the opening of cation channels, after calcium release, and thus the ER membrane potential is maintained. Disruption of intracellular calcium kinetics affects the activity of many proteins required for type I collagen synthesis and folding[48,49]. Webb *et al*[50] revealed characteristics of bone modifications in patients with biallelic *TMEM38B* pathogenic variants:Decreased hydroxylation of collagen helical lysine residues and intracellular retention and degradation of misfolded collagen. The phenotypic spectrum varies considerably ranging from mild scoliosis to severe cases with prenatal bowed femur, early-onset multiple fractures, and growth retardation (OI type XIV). The variability in phenotype severity indicates that other factors may be involved, including genetic modifiers, different genetic backgrounds, and other genes involved in intracellular calcium dynamics. Patients responded well to BPs, but, in some cases, cardiovascular abnormalities and hypotonia were reported (possibly related to abnormal ER calcium kinetics)[51-54].

***WNT1***

Proto-oncogene Wnt-1 (the wingless-type mouse mammary tumor virus integration site family, member 1) is a glycoprotein with a key role in bone development. WNT1interacts with the cell surface lipoprotein receptor-related protein 5 (LRP5) and Frizzled receptor leading to the translocation and accumulation of beta-catenin into the cell nucleus and subsequent transcriptional regulation of target genes. WNT/β-catenin signaling is involved in osteoblast progenitor proliferation, osteoblast differentiation, and regulation of osteoclastogenesis in mature osteoblasts and osteocytes through the secretion of osteoprotegerin[55-57]. The WNT/β-catenin pathway is an activator of *BMP2* gene transcription, a member of the TGF-β gene superfamily essential for osteoblast differentiation and osteogenesis[57]. Biallelic pathogenic variants in *WNT1* gene lead to moderate-severe OI, whereas heterozygous *WNT1* gene mutations are reported in patients with ‘early-onset osteoporosis’ indicating a gene dose effect. Neurologic features such as hypotonia, ptosis, developmental delays, and brain anomalies have been reported in some patients with OI type XV[57-60].

***CREB3L1***

Cyclic AMP-responsive element-binding protein 3-like protein 1 (CREB3L1), also known as old astrocyte specifically induced substance (OASIS), a leucine zipper transcription factor is encoded by *CREB3L1* gene. In osteoblasts, CREB3L1 is activated by regulated intramembrane proteolysis (RIP) and induces the transcription of *COL1A1* gene by binding to the UPR element-like sequence in itspromoter. Also, CREB3L1 plays an important role in the expression of coat protein complex II component SEC24D, involved in procollagen export from ER[45,61,62]. Phenotype severity varies considerably ranging from forms with prenatal fractures, severe demineralization, and early lethal outcome to cases with severe bone deformities and survival to adulthood (OI type XVI). Severe phenotypes are caused by homozygous whole gene deletions or in frame deletions in a highly conserved DNA binding domain (loss of function). Siblings with heterozygous pathogenic variants are mildly affected: fractures with minimal trauma, blue sclerae, and osteopenia[61,63]. Truncating homozygous pathogenic variants (outside the highly conserved DNA binding domain) led to a non-lethal phenotype, while heterozygotes are unaffected[64,65].

***SPARC***

Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or basement membrane protein 40, has a collagen-binding domain and a hydroxyapatite (necessary for mineralization of the collagenous matrix) binding site. During bone development, SPARC is secreted by osteoblasts and has important roles in procollagen processing and assembly in the bone matrix, cross linking, and mineralization[66,67]. Pathogenic variants (substitution, nonsense or splice site) that affect the collagen-binding domain have been reported in patients with OI. Common features of this type of OI (OI type XVII) are multiple postnatal fractures, scoliosis, delayed motor development, neuromuscular weakness (especially of the lower extremities), and brain MRI abnormalities[68-70].

***TENT5A***

Terminal nucleotidyltransferase 5A (TENT5A) belongs to the nucleotidyltransferase fold superfamily proteins and acts as a noncanonical poly(A) polymerase. TENT5A forms a complex with SMAD proteins and induces transcription of BMP target genes. TENT5A is involved in embryonic development, adult bone formation, and hemin-induced hemoglobinization[2,71,72]. Doyard *et al*[73] reported biallelic pathogenic variants (nonsense or missense) in *TENT5A* genes in patients with a severe form of OI (OI type XVIII) with multiple fractures, severe bowing of lower limbs, joint hyperlaxity, vertebral collapses, and blue sclerae. Lin *et al*[71] considered TENT5A a molecular modulator and a future therapeutic target.

***MBTPS2***

An X-linked form of OI (OI type XIX) is caused by a mutation in *MBTPS2*, a gene that encodes the membrane-bound transcription factor protease, site-2 (MBTPS2), also known as site-2 protease, a component of the RIP pathway. ER stress - due to retention of unfolded proteins - leads to translocation of CREB3L1, sterol regulatory element-binding protein, and activating transcription factor 6, from the ER membrane to the Golgi membrane, where they are cleaved by endoproteases MBTPS1 and MBTPS2. The resulting fragments regulate the production of collagen and matrix components in the nucleus[1,2,74]. Substitutions that affect a highly conserved MBTPS2 motif, essential for zinc ion coordinating site, are associated with reduced hydroxylation of lysine 87 in both α collagen chains and altered collagen cross-linking. Patients have a form of moderate-to-severe OI with prenatal fractures, generalized osteopenia, long bone bowing, short stature, pectus deformity, and scoliosis, but no dermatological features[75]. Missense pathogenic variants elsewhere in *MBTPS2* have been associated with dermatological conditions - IFAP (ichthyosis follicularis, atrichia, and photophobia) syndrome with or without BRESHECK (Brain anomalies, severe mental Retardation, Ectodermal dysplasia, Skeletal deformities, Ear/eye and Kidney dysplasia/hypoplasia) syndrome, Olmsted syndrome (mutilating palmoplantar keratoderma with periorificial keratotic plaques), and keratosis follicularis spinulosa decalvans[76-78].

***MESD***

*MESD* gene (mesoderm development) encodes an ER chaperone for the WNT signaling receptors LRP5 and LRP6. Moosa *et al*[79] reported patients with biallelic pathogenic variants (frameshift predicted to result in a premature termination codon or substitution that removes a highly conserved domain) in exon 3 of *MESD* gene, with partial loss of function, and a progressively deforming type of OI with oligodontia and developmental delay. BPs were not effective in these patients, but antisclerostin antibodies that affect Wnt signaling could be a valid therapeutic option. Two infant deaths due to respiratory insufficiency were reported. Stürznickel *et al*[80] reported three stillbirths with multiple intrauterine fractures and compound heterozygous frameshift pathogenic variants in exon 2 and exon 3 of *MESD* gene. They blamed the lethal phenotype on a complete loss of function mutation, located within the chaperone domain of MESD (exon 2)[80].

***KDELR2***

*KDELR2* gene encodes ER lumen protein-retaining receptor 2, involved in protein with a KDEL-like peptide traffic from the Golgi to the ER. The protein binds heat shock protein 47 (HSP47), with an essential role in the intracellular processing of procollagen. Biallelic pathogenic variants in *KDELR2* gene are associated with abnormal collagen fibril formation due to the failure of HSP47 to dissociate from collagen type 1. Patients present a progressively deforming type of OI. Efthymiou *et al*[81] reported neurodevelopmental disorders (motor and speech delay) in three cases[82].

***CCDC134***

*CCDC134* gene encodes a secreted coiled-coil domain-containing protein, involved in the regulation of MAPK pathway, especially phosphorylation of the extracellular signal-related kinase (Erk) or c-JUN N-terminal kinase (JUNK). Erk1/2 and JUNK have an important role in bone morphogenesis, by regulating osteoblast extracellular matrix protein deposition in response to stress. Loss of function pathogenic variants in *CCDC134* gene were associated withreduced *COL1A1* and *SPP1* (ostepontin)mRNA expression and mineralization in osteoblasts. Dubail *et al*[83] reported patients with homozygous pathogenic variants in *CCDC134* gene and a severe form of OI with intrauterine growth retardation, multiple pre and postnatal fractures, short stature, low mineral density, and no response to BPs[84,85].

**GENETIC COUNSELING AND PROPHYLAXIS**

The identification of the inheritance pattern is essential for genetic counseling and management. Up to 90% of OI patients have an AD pathogenic variant in *COL1A1, COL1A2,* or *IFITM5* genes, with a 50% risk to transmit this variant to their offspring[86]. Nearly half of the OI cases are caused by *de novo* pathogenic variants[87]. Although advanced paternal age is associated with a high risk of *de novo* pathogenic variants in monogenic disorders, Mei *et al*[88] reported a significantly younger paternal and maternal age at conception in OI patients with a *de novo* mutation. Pyott *et al*[89] reported a 16% rate of parental mosaicism in couples with a child affected by lethal AD OI. In couples with two or more children with lethal AD OI, the recurrence rate of this mosaicism was 27%[89]. The rate of parental mosaicism is estimated at approximately 5–8% in all OI cases[86]. Persons with mosaicism for AD pathogenic variants are often asymptomatic or have subtle clinical findings depending on the percentage of cells that carry the pathogenic variant[88].

About 10% of OI patients have pathogenic variants with autosomal recessive (AR) inheritance. The distribution of these AR variants is different across populations due to consanguinity or founder effect. In a genetically isolated Dutch group, the carrier frequency of a *CRTAP* frameshift variant was 4.1% while in the general Dutch population is < 0.2%[90]. Founder pathogenic variants in other genes associated with recessive OI have been reported: *P3H1* in West African, United States African American populations and ethnic Kinhs, *TMEM38B* in Palestinians, and Israeli Arab Bedouins, *FKBP10* in indigenous southern Africans, Palestinians, Bavarians, and Samoan islanders, *SEC24D* in southwestern Germans, *WNT1* in the Finnish Hmong group, and *PPIB* in Chinese people[33,91-95]. A few cases with X-linked pathogenic variants in *MBTPS2* or *PLS3* have also been reported[75,96].

Genetic testing is essential for the identification of pathogenic variants, inheritance pattern, and differential diagnosis. Based on the clinical and radiographic features, and family history either the sequencing of *COL1A1* and *COL1A2* or a comprehensive next-generation sequencing panel (all OI genes and genes associated with skeletal dysplasia) is initially recommended. The interpretation of genetic testing results can sometimes be challenging: Identifying unknown significance variants, or sequence variants in a new gene (not previously reported in OI cases). Genotype-phenotype correlations are sometimes difficult to establish, due to the wide OI phenotypical variability, in association with genetic or epigenetic modifiers[97]. Some OI lethality/ severity prediction algorithms were established with variable accuracy[98].

Preconception carrier screening is recommended in healthy couples in different circumstances: positive OI family history, consanguineous marriage, or members of founder populations. Carrier screening cannot detect parental germline mosaicism or predict the possibility of *de novo* pathogenic variants. A couple with a significant recurrence risk - affected parent(s), carriers of AR pathogenic variants - has many reproductive options: *In vitro* fertilization (IVF) with gamete or embryo donation, IVF with own cells, and preimplantation genetic diagnosis (PGD), adoption, or natural pregnancy with prenatal diagnosis. Gamete donation is usually recommended in couples with infertility or affected women, because repeated superovulation procedures are associated with an increased risk of osteoporosis and cardiovascular problems[99]. PGD has the advantage of also detecting aneuploidies, but the accuracy rate is 95 to 99.5%, so there is a small risk of false negative results. Moreover, the success rate for artificial reproductive techniques is below 30%. Prenatal testing should be recommended after implantation to confirm the PGD result. In this context, a debatable issue is the transfer of AR variants heterozygous embryos. A parental argument not to transfer an AR carrier embryo would be the prevention of difficult reproductive options for the future child[86,100,101].

***Prenatal testing***

Prenatal genetic testing includes non-invasive prenatal testing (NIPT), and invasive techniques. NIPT has the advantages of early testing (first trimester), less invasive procedure (circulating cell-free fetal DNA extracted from maternal blood), and no associated miscarriage risk. The disadvantages of NIPT are the risk of false-positive, false-negative, or inconclusive results due to confined placental mosaicism (the trophoblastic origin of cell-free fetal DNA is associated with a much higher mutation rate than other fetus cells), or vanishing twin syndrome. NIPT is technically challenging for X-linked and for AR forms when both parents are carriers of the same pathogenic variant due to the presence of the relevant variant from maternal cells in the circulating cell-free DNA. Moreover, NIPT does not cover all the genes involved in OI pathogeny. NIPT results should be confirmed by invasive prenatal testing[102-106].

Invasive prenatal testing uses fetal cells extracted by chorionic villus sampling (CVS), amniocentesis, or cordocentesis, and is associated with an increased risk of pregnancy complications, including fetal loss. CVS has an associated risk of false results due to confined placental mosaicism but allows biochemical type I collagen analysis in extracted cells. Amniocentesis avoids misdiagnosis due to placental mosaicism or twin pregnancy but is performed in the second trimester, after 15 wk of pregnancy, and thus means a long distressful waiting period for the couple. Prenatal diagnosis allows pregnancy management decisions, including the alternative to terminate pregnancy or options for mode of delivery, early OI treatment, before (mesenchymal stem cell transplantation), or after birth[86,107,108].

***Ultrasound screening***

Severe and lethal forms of OI could be detected by ultrasound screening in the second trimester. Abnormal ultrasound findings suggestive of severe OI include long bone shortening (especially femur length), bowing, and multiple fractures. Moreover, lethal forms have severe demineralization with a thin, easily compressible calvarium, and no posterior acoustic shadowing from long bones[107,109]. Femur length-to-abdominal circumference ratio < 0.16, fetal lung volume below the fifth percentile for gestational age (measured by ultrasound or MRI), and polyhydramnios were associated with lethal outcome. Ultrasound findings do not allow an accurate differential diagnosis with other skeletal dysplasias[107,110,111]. Three-dimensional helical computed tomography provides more accurate data about skeletal anomalies but there are concerns regarding the safety of radiation exposure (even to low doses)[112].

***Mode of delivery***

In the past, cesarean delivery was considered safer and more useful for the prevention of fractures at birth than vaginal delivery. Recent studies on babies with types I, III and IV of OI showed that the delivery mode does not influence the rate of fractures at birth. Also, the breech presentation seems to be more frequent in OI type III. Bellur *et al* suggested that cesarean delivery should be performed only for usual maternal or fetal indications, not for fracture prevention in OI. Pregnant women affected by OI require close monitoring to detect possible complications such as cardiorespiratory problems, bone loss, cephalopelvic disproportion, uterine and placenta rupture, and excessive bleeding at delivery[107,113-115].

***Therapy***

The OI treatment includes physical therapy, medication, and surgical procedures. The major goals are the prevention of fractures, and deformities, maximizing the patient's functional ability, and reducing pain. Fracture healing might be delayed in cases with pathogenic *WNT1* gene variants, or might be altered by hyperplastic callus formation in patients with pathogenic *IFITM5* gene variants. Surgical procedures are used for complex fractures or when correction of deformities is necessary. Intramedullary telescopic rods are used during growth because these have the ability to lengthen. OI patients have anesthetic risks due to abnormal shape or airway, impaired lung function, or the possibility of cervical spine fracture during intubation[4,116]. The rate of fractures decreases in adulthood but the risk of joint osteoarthritis increases[13]. Physiotherapy is essential to improve mobility, due to hypotonia and ligament laxity. Obstructive pulmonary disease (type I collagen is present in lung parenchyma) and scoliosis lead to respiratory complications, a major cause of mortality in OI[117]. Cardiovascular complications include aortic root dilatation left valvular regurgitation, and aortic root dilatation with dissection risk[118]. A multi-disciplinary approach is recommended to address problems related to bone fragility, and also extra-skeletal manifestations.

***Antiresorptive bone therapy***

BPs are currently the most commonly used pharmacological agents in the treatment of pediatric OI. BPs bind to the hydroxyapatite crystals, promote osteoclasts apoptosis, and decrease bone resorption and remodeling. BPs also interact with osteocytes and interfere with osteoblast recruitment on eroded surfaces[119]. Intravenous infusion is superior to oral administration in improving BMD and decreasing fracture rate. Studies reported that maximum benefits are obtained after 3 years of treatment, but there is no difference in adult fracture rates[120-123]. Long-term treatment is associated with microcrack accumulation and increased potential of progression into fractures, loss of microstructural integrity, and reduced mechanical strength[124]. Another disadvantage of BPs is their long half-life; BPs persist in the bone for years after drug discontinuation. Green *et al*[125] reported decreased birth weight and transient neonatal electrolyte abnormalities (hypocalcemia, hypercalcemia, hyperphosphatemia) associated with maternal use of BPs before or during pregnancy. Whether BPs should be used for a long time at similar or lower doses is debatable. Also, BPs do not have the same efficiency in all types of OI[13,126].

Denosumab is a monoclonal antibody that targets RANKL and inhibits osteoclast activity without binding to the bone. The mechanism of action is similar to BPs, antiresorptive. Denosumab has a shorter half-life (months) and showed promising results in increasing BMD in a few studies. Further studies are necessary to assess the efficiency of fracture prevention[126,127].

*Osteo-anabolic agents*

Osteo-anabolic therapies stimulate osteoblast activity and bone formation, instead of inhibiting osteoclast function as antiresorptive. Growth hormone (GH) has been used to stimulate long bone growth in GH deficiency, but GH therapy showed only limited benefits in increasing bone mass density compared to BPs (mostly in OI type IV). GH has been less efficient in the more severe forms of OI (type III)[128,129]. Teriparatide, a recombinant parathyroid hormone, leads to a significant increase in BMD in adults with type I OI but seems less effective in patients with types III and IV. Teriparatide has not been used for more than 24 mo and its use in children is contraindicated due to the concern of increased risk of osteosarcoma reported by animal studies[116,129-131]. Lately, the US FDA removed the warning because the risk was only confined to animal studies.

Sclerostin-inhibitory antibodies, romosozumab, and setrusumab, neutralize sclerostin, a negative regulator of Wnt signaling in osteoblasts. Studies revealed good responses of BMD and bone turnover markers to sclerostin-inhibitory antibody treatment in adults with OI[132,133]. Lv *et al*[134] revealed that romosozumab might increase the risk of cardiovascular adverse events in the elderly.

Animal studies have shown that TGF-β signaling is an essential element of pathogenesis, and blocking TGF-β improves bone mass and biomechanical properties, so anti-TGF-antibodies could represent a valuable therapeutic option. Song *et al*[135] reported an increase of BMD in children with type IV OI treated with fresolimumab (an anti-TGF-antibody), but no effect in type III and VIII OI. Losartan, an angiotensin II receptor blocker may also have anti-TGF properties[135]. Losartan increased bone mass and accelerated chondrocyte hypertrophy in the growth plate in an animal study[136].

*Cell therapy and gene editing*

Stem cell therapy is a promising pre and postnatal option based on the cells’ ability to differentiate into osteoblasts that produce normal collagen. Transplantation of bone marrow from HLA-matched siblings and prenatal and postnatal transplantation of mesenchymal stem cells have been associated with improved growth and reduction of fractures rate. In the first group (bone marrow from HLA-matched siblings), the effect was transient, the growth rate slowed over time and a second transplantation with bone marrow/mesenchymal stem cells has been used. There is limited experience in this area, so further trials are necessary[137,138]. The application of cellular reprogramming to create induced pluripotent stem cells (iPSCs) opens a new therapeutic approach.

Advances in gene editing technology bring the possibility of correcting the pathogenic variant. A recent approach involves the silencing of a dominant (gain of function) pathogenic variant, leading to allele suppression and converting the severe forms into a milder phenotype. Different strategies have been used: Antisense oligonucleotides, short interfering RNA, and hammerhead ribozymes. Another approach, gene addition therapy, involves the correction of the expression of deficient or absent alleles in affected cells. In cases where an abnormal collagen chain is produced and affects triple helix assembly, this method will not influence the phenotype. The efficiency of gene editing is still debatable, there are no data about the duration of the positive effects, and concerns regarding off‐target effects, risks of an immune response, and genotoxicity are raised. Clinical trials are needed[126,139].

The combination of the CRISPR–Cas9 gene editing tool with induced pluripotent stem cells may improve therapeutic options. Jung *et al*[140] demonstrated the restoration of type I collagen expression in iPSCs in an OI patient corrected by the CRISPR–Cas9 system.

A new promising therapy is the chemical chaperone 4-phenylbutyrate (4-PBA), involved in protein folding and aggregation in ER. 4-PBA also has histone deacetylase inhibitor activity. Experimental studies reported the reduction of fracture rate and improvement of growth deficiency in animal OI models after 4-BPA treatment[141,142].

**CONCLUSION**

In recent decades, great progress has been made in identifying genes and molecular mechanisms underlying OI. These advances demonstrate that OI is an extremely heterogeneous collagen-related disease. The classical clinical Sillence classification is now partially revolute, and the involvement of different causative genes and the presence of different inheritance patterns generate challenges for genetic counseling. However, genetic classification allows an accurate identification of the inheritance for family planning, and offers the possibility of the development of genotype-based therapeutic approaches.

**REFERENCES**

1 **Marini JC**, Forlino A, Bächinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D, Montpetit K, Semler O. Osteogenesis imperfecta. *Nat Rev Dis Primers* 2017; **3**: 17052 [PMID: 28820180 DOI: 10.1038/nrdp.2017.52]

2 **Jovanovic M**, Guterman-Ram G, Marini JC. Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types. *Endocr Rev* 2022; **43**: 61-90 [PMID: 34007986 DOI: 10.1210/endrev/bnab017]

3 **Chretien A**, Couchot M, Mabilleau G, Behets C. Biomechanical, Microstructural and Material Properties of Tendon and Bone in the Young Oim Mice Model of Osteogenesis Imperfecta. *Int J Mol Sci* 2022; **23** [PMID: 36077325 DOI: 10.3390/ijms23179928]

4 **Etich J**, Leßmeier L, Rehberg M, Sill H, Zaucke F, Netzer C, Semler O. Osteogenesis imperfecta-pathophysiology and therapeutic options. *Mol Cell Pediatr* 2020; **7**: 9 [PMID: 32797291 DOI: 10.1186/s40348-020-00101-9]

5 **Marom R**, Rabenhorst BM, Morello R. Osteogenesis imperfecta: an update on clinical features and therapies. *Eur J Endocrinol* 2020; **183**: R95-R106 [PMID: 32621590 DOI: 10.1530/EJE-20-0299]

6 **Amirrah IN**, Lokanathan Y, Zulkiflee I, Wee MFMR, Motta A, Fauzi MB. A Comprehensive Review on Collagen Type I Development of Biomaterials for Tissue Engineering: From Biosynthesis to Bioscaffold. *Biomedicines* 2022; **10** [PMID: 36140407 DOI: 10.3390/biomedicines10092307]

7 **Ishikawa Y**, Taga Y, Zientek K, Mizuno N, Salo AM, Semenova O, Tufa SF, Keene DR, Holden P, Mizuno K, Gould DB, Myllyharju J, Bächinger HP. Type I and type V procollagen triple helix uses different subsets of the molecular ensemble for lysine posttranslational modifications in the rER. *J Biol Chem* 2021; **296**: 100453 [PMID: 33631195 DOI: 10.1016/j.jbc.2021.100453]

8 **Marini JC**, Reich A, Smith SM. Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation. *Curr Opin Pediatr* 2014; **26**: 500-507 [PMID: 25007323 DOI: 10.1097/MOP.0000000000000117]

9 **Sharma U**, Carrique L, Vadon-Le Goff S, Mariano N, Georges RN, Delolme F, Koivunen P, Myllyharju J, Moali C, Aghajari N, Hulmes DJ. Structural basis of homo- and heterotrimerization of collagen I. *Nat Commun* 2017; **8**: 14671 [PMID: 28281531 DOI: 10.1038/ncomms14671]

10 **Sillence DO**, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. *J Med Genet* 1979; **16**: 101-116 [PMID: 458828 DOI: 10.1136/jmg.16.2.101]

11 **Van Dijk FS**, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. *Am J Med Genet A* 2014; **164A**: 1470-1481 [PMID: 24715559 DOI: 10.1002/ajmg.a.36545]

12 **Mortier GR**, Cohn DH, Cormier-Daire V, Hall C, Krakow D, Mundlos S, Nishimura G, Robertson S, Sangiorgi L, Savarirayan R, Sillence D, Superti-Furga A, Unger S, Warman ML. Nosology and classification of genetic skeletal disorders: 2019 revision. *Am J Med Genet A* 2019; **179**: 2393-2419 [PMID: 31633310 DOI: 10.1002/ajmg.a.61366]

13 **Forlino A**, Marini JC. Osteogenesis imperfecta. *Lancet* 2016; **387**: 1657-1671 [PMID: 26542481 DOI: 10.1016/S0140-6736(15)00728-X]

14 **Symoens S**, Hulmes DJ, Bourhis JM, Coucke PJ, De Paepe A, Malfait F. Type I procollagen C-propeptide defects: study of genotype-phenotype correlation and predictive role of crystal structure. *Hum Mutat* 2014; **35**: 1330-1341 [PMID: 25146735 DOI: 10.1002/humu.22677]

15 **Cabral WA**, Mertts MV, Makareeva E, Colige A, Tekin M, Pandya A, Leikin S, Marini JC. Type I collagen triplet duplication mutation in lethal osteogenesis imperfecta shifts register of alpha chains throughout the helix and disrupts incorporation of mutant helices into fibrils and extracellular matrix. *J Biol Chem* 2003; **278**: 10006-10012 [PMID: 12538651 DOI: 10.1074/jbc.M212523200]

16 **Marini JC**, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. *Hum Mutat* 2007; **28**: 209-221 [PMID: 17078022 DOI: 10.1002/humu.20429]

17 Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University Baltimore: Baltimore, MD, USA. 2022 [cited 2022 October 14]. Database: omim [Internet]. Available from: https://omim.org/

18 **HGNC**. HUGO Gene Nomenclature Committee Home Page; 2022 [cited 2022 November 5]. Database: genenames [Internet]. Available from: http://www.genenames.org/

19 UniProt: the Universal Protein Knowledgebase; 2023 [cited 2022 November 12]. Database: uniprot [Internet]. Available from: https://www.uniprot.org/

20 **Cho TJ**, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. *Am J Hum Genet* 2012; **91**: 343-348 [PMID: 22863190 DOI: 10.1016/j.ajhg.2012.06.005]

21 **Semler O**, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, Iden S, Wirth B, Eysel P, Koerber F, Schoenau E, Bohlander SK, Wollnik B, Netzer C. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. *Am J Hum Genet* 2012; **91**: 349-357 [PMID: 22863195 DOI: 10.1016/j.ajhg.2012.06.011]

22 **Shapiro F**, Maguire K, Swami S, Zhu H, Flynn E, Wang J, Wu JY. Histopathology of osteogenesis imperfecta bone. Supramolecular assessment of cells and matrices in the context of woven and lamellar bone formation using light, polarization and ultrastructural microscopy. *Bone Rep* 2021; **14**: 100734 [PMID: 33665234 DOI: 10.1016/j.bonr.2020.100734]

23 **Lim JY**, Bhatia NS, Vasanwala RF, Chay PL, Lim KBL, Khoo PC, Schwarze U, Jamuar SS. A novel Ser40Trp variant in IFITM5 in a family with osteogenesis imperfecta and review of the literature. *Clin Dysmorphol* 2019; **28**: 120-125 [PMID: 30985308 DOI: 10.1097/MCD.0000000000000279]

24 **Dagdeviren D**, Tamimi F, Lee B, Sutton R, Rauch F, Retrouvey JM. Dental and craniofacial characteristics caused by the p.Ser40Leu mutation in IFITM5. *Am J Med Genet A* 2019; **179**: 65-70 [PMID: 30289614 DOI: 10.1002/ajmg.a.40383]

25 **Zeitlin L**, Rauch F, Travers R, Munns C, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. *Bone* 2006; **38**: 13-20 [PMID: 16162424 DOI: 10.1016/j.bone.2005.07.020]

26 **Kang H**, Aryal Ac S, Barnes AM, Martin A, David V, Crawford SE, Marini JC. Antagonism Between PEDF and TGF-β Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis. *J Bone Miner Res* 2022; **37**: 925-937 [PMID: 35258129 DOI: 10.1002/jbmr.4540]

27 **Amorim DMR**, Koga GKC, Dos Santos RN, Secundo PFC, de Ávila Fernandes E, Cardili L, Maeda SS, da Rocha Corrêa Fernandes A, Lazaretti-Castro M. Rare Association Between Osteogenesis Imperfecta and Chondrosarcoma: Could a Pathogenic Variant in the Gene SERPINF1 Explain It? *Calcif Tissue Int* 2023; **112**: 118-122 [PMID: 36322168 DOI: 10.1007/s00223-022-01033-4]

28 **Hoyer-Kuhn H**, Netzer C, Koerber F, Schoenau E, Semler O. Two years' experience with denosumab for children with osteogenesis imperfecta type VI. *Orphanet J Rare Dis* 2014; **9**: 145 [PMID: 25257953 DOI: 10.1186/s13023-014-0145-1]

29 **Chang W**, Barnes AM, Cabral WA, Bodurtha JN, Marini JC. Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex. *Hum Mol Genet* 2010; **19**: 223-234 [PMID: 19846465 DOI: 10.1093/hmg/ddp481]

30 **Barnes AM**, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. *N Engl J Med* 2006; **355**: 2757-2764 [PMID: 17192541 DOI: 10.1056/NEJMoa063804]

31 **Morello R**, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bächinger HP, Pace JM, Schwarze U, Byers PH, Weis M, Fernandes RJ, Eyre DR, Yao Z, Boyce BF, Lee B. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. *Cell* 2006; **127**: 291-304 [PMID: 17055431 DOI: 10.1016/j.cell.2006.08.039]

32 **van Dijk FS**, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MH, Elting MW, Verbeke JI, Wijnaendts LC, Shaw NJ, Högler W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G. PPIB mutations cause severe osteogenesis imperfecta. *Am J Hum Genet* 2009; **85**: 521-527 [PMID: 19781681 DOI: 10.1016/j.ajhg.2009.09.001]

33 **Zhytnik L**, Duy BH, Eekhoff M, Wisse L, Pals G, Reimann E, Kõks S, Märtson A, Maugeri A, Maasalu K, Micha D. Phenotypic Variation in Vietnamese Osteogenesis Imperfecta Patients Sharing a Recessive P3H1 Pathogenic Variant. *Genes (Basel)* 2022; **13** [PMID: 35327962 DOI: 10.3390/genes13030407]

34 **Ito S**, Nagata K. Biology of Hsp47 (Serpin H1), a collagen-specific molecular chaperone. *Semin Cell Dev Biol* 2017; **62**: 142-151 [PMID: 27838364 DOI: 10.1016/j.semcdb.2016.11.005]

35 **Schwarze U**, Cundy T, Liu YJ, Hofman PL, Byers PH. Compound heterozygosity for a frameshift mutation and an upstream deletion that reduces expression of SERPINH1 in siblings with a moderate form of osteogenesis imperfecta. *Am J Med Genet A* 2019; **179**: 1466-1475 [PMID: 31179625 DOI: 10.1002/ajmg.a.61170]

36 **Syx D**, Ishikawa Y, Gebauer J, Boudko SP, Guillemyn B, Van Damme T, D'hondt S, Symoens S, Nampoothiri S, Gould DB, Baumann U, Bächinger HP, Malfait F. Aberrant binding of mutant HSP47 affects posttranslational modification of type I collagen and leads to osteogenesis imperfecta. *PLoS Genet* 2021; **17**: e1009339 [PMID: 33524049 DOI: 10.1371/journal.pgen.1009339]

37 **Barnes AM**, Duncan G, Weis M, Paton W, Cabral WA, Mertz EL, Makareeva E, Gambello MJ, Lacbawan FL, Leikin S, Fertala A, Eyre DR, Bale SJ, Marini JC. Kuskokwim syndrome, a recessive congenital contracture disorder, extends the phenotype of FKBP10 mutations. *Hum Mutat* 2013; **34**: 1279-1288 [PMID: 23712425 DOI: 10.1002/humu.22362]

38 **Lim J**, Lietman C, Grol MW, Castellon A, Dawson B, Adeyeye M, Rai J, Weis M, Keene DR, Schweitzer R, Park D, Eyre DR, Krakow D, Lee BH. Localized chondro-ossification underlies joint dysfunction and motor deficits in the Fkbp10 mouse model of osteogenesis imperfecta. *Proc Natl Acad Sci U S A* 2021; **118** [PMID: 34161280 DOI: 10.1073/pnas.2100690118]

39 **Otaify GA**, Abdel-Hamid MS, Hassib NF, Elhossini RM, Abdel-Ghafar SF, Aglan MS. Bruck syndrome in 13 new patients: Identification of five novel FKBP10 and PLOD2 variants and further expansion of the phenotypic spectrum. *Am J Med Genet A* 2022; **188**: 1815-1825 [PMID: 35278031 DOI: 10.1002/ajmg.a.62718]

40 **Hojo H**, Ohba S. Sp7 Action in the Skeleton: Its Mode of Action, Functions, and Relevance to Skeletal Diseases. *Int J Mol Sci* 2022; **23** [PMID: 35628456 DOI: 10.3390/ijms23105647]

41 **Lapunzina P**, Aglan M, Temtamy S, Caparrós-Martín JA, Valencia M, Letón R, Martínez-Glez V, Elhossini R, Amr K, Vilaboa N, Ruiz-Perez VL. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. *Am J Hum Genet* 2010; **87**: 110-114 [PMID: 20579626 DOI: 10.1016/j.ajhg.2010.05.016]

42 **Ludwig K**, Ward LM, Khan N, Robinson ME, Miranda V, Bardai G, Moffatt P, Rauch F. Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant. *Bone* 2022; **160**: 116400 [PMID: 35367406 DOI: 10.1016/j.bone.2022.116400]

43 **Lui JC**, Raimann A, Hojo H, Dong L, Roschger P, Kikani B, Wintergerst U, Fratzl-Zelman N, Jee YH, Haeusler G, Baron J. A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder. *Nat Commun* 2022; **13**: 700 [PMID: 35121733 DOI: 10.1038/s41467-022-28318-4]

44 **Campanini EH**, Baker D, Arundel P, Bishop NJ, Offiah AC, Keigwin S, Cadden S, Dall'Ara E, Nicolaou N, Giles S, Fernandes JA, Balasubramanian M. High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1. *Bone Rep* 2021; **15**: 101102 [PMID: 34277895 DOI: 10.1016/j.bonr.2021.101102]

45 **Claeys L**, Storoni S, Eekhoff M, Elting M, Wisse L, Pals G, Bravenboer N, Maugeri A, Micha D. Collagen transport and related pathways in Osteogenesis Imperfecta. *Hum Genet* 2021; **140**: 1121-1141 [PMID: 34169326 DOI: 10.1007/s00439-021-02302-2]

46 **Pollitt RC**, Saraff V, Dalton A, Webb EA, Shaw NJ, Sobey GJ, Mughal MZ, Hobson E, Ali F, Bishop NJ, Arundel P, Högler W, Balasubramanian M. Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations. *Am J Med Genet A* 2016; **170**: 3150-3156 [PMID: 27576954 DOI: 10.1002/ajmg.a.37958]

47 **Zhang Y**, Chen B, Li D, Zhou X, Chen Z. LncRNA NEAT1/miR-29b-3p/BMP1 axis promotes osteogenic differentiation in human bone marrow-derived mesenchymal stem cells. *Pathol Res Pract* 2019; **215**: 525-531 [PMID: 30638953 DOI: 10.1016/j.prp.2018.12.034]

48 **Cabral WA**, Ishikawa M, Garten M, Makareeva EN, Sargent BM, Weis M, Barnes AM, Webb EA, Shaw NJ, Ala-Kokko L, Lacbawan FL, Högler W, Leikin S, Blank PS, Zimmerberg J, Eyre DR, Yamada Y, Marini JC. Absence of the ER Cation Channel TMEM38B/TRIC-B Disrupts Intracellular Calcium Homeostasis and Dysregulates Collagen Synthesis in Recessive Osteogenesis Imperfecta. *PLoS Genet* 2016; **12**: e1006156 [PMID: 27441836 DOI: 10.1371/journal.pgen.1006156]

49 **Leoni L**, Tonelli F, Besio R, Gioia R, Moccia F, Rossi A, Forlino A. Knocking out TMEM38B in human foetal osteoblasts hFOB 1.19 by CRISPR/Cas9: A model for recessive OI type XIV. *PLoS One* 2021; **16**: e0257254 [PMID: 34582479 DOI: 10.1371/journal.pone.0257254]

50 **Webb EA**, Balasubramanian M, Fratzl-Zelman N, Cabral WA, Titheradge H, Alsaedi A, Saraff V, Vogt J, Cole T, Stewart S, Crabtree NJ, Sargent BM, Gamsjaeger S, Paschalis EP, Roschger P, Klaushofer K, Shaw NJ, Marini JC, Högler W. Phenotypic Spectrum in Osteogenesis Imperfecta Due to Mutations in TMEM38B: Unraveling a Complex Cellular Defect. *J Clin Endocrinol Metab* 2017; **102**: 2019-2028 [PMID: 28323974 DOI: 10.1210/jc.2016-3766]

51 **Ramzan K**, Alotaibi M, Huma R, Afzal S. Detection of a Recurrent TMEM38B Gene Deletion Associated with Recessive Osteogenesis Imperfecta. *Discoveries (Craiova)* 2021; **9**: e124 [PMID: 34036147 DOI: 10.15190/d.2021.3]

52 **Shaheen R**, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N, Mousa N, Alsinani A, Ansari S, Alzahrani F, Al-Owain M, Alzayed ZS, Alkuraya FS. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. *J Med Genet* 2012; **49**: 630-635 [PMID: 23054245 DOI: 10.1136/jmedgenet-2012-101142]

53 **Volodarsky M**, Markus B, Cohen I, Staretz-Chacham O, Flusser H, Landau D, Shelef I, Langer Y, Birk OS. A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta. *Hum Mutat* 2013; **34**: 582-586 [PMID: 23316006 DOI: 10.1002/humu.22274]

54 **Lv F**, Xu XJ, Wang JY, Liu Y, Asan, Wang JW, Song LJ, Song YW, Jiang Y, Wang O, Xia WB, Xing XP, Li M. Two novel mutations in TMEM38B result in rare autosomal recessive osteogenesis imperfecta. *J Hum Genet* 2016; **61**: 539-545 [PMID: 26911354 DOI: 10.1038/jhg.2016.11]

55 **Laine CM**, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, Lu JT, Pekkinen M, Wessman M, Heino TJ, Nieminen-Pihala V, Aronen M, Laine T, Kröger H, Cole WG, Lehesjoki AE, Nevarez L, Krakow D, Curry CJ, Cohn DH, Gibbs RA, Lee BH, Mäkitie O. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. *N Engl J Med* 2013; **368**: 1809-1816 [PMID: 23656646 DOI: 10.1056/NEJMoa1215458]

56 **Lu Y**, Dai Y, Wang Y, Zhai N, Zhang J, Liu J, Yin X, Li T, Ren X, Han J. Complex heterozygous WNT1 mutation in severe recessive osteogenesis imperfecta of a Chinese patient. *Intractable Rare Dis Res* 2018; **7**: 19-24 [PMID: 29552441 DOI: 10.5582/irdr.2018.01014]

57 **Zhang B**, Li R, Wang W, Zhou X, Luo B, Zhu Z, Zhang X, Ding A. The role of WNT1 mutant variant (WNT1) (c.677C>T) in osteogenesis imperfecta. *Ann Hum Genet* 2020; **84**: 447-455 [PMID: 32757296 DOI: 10.1111/ahg.12399]

58 **Mäkitie O**, Zillikens MC. Early-Onset Osteoporosis. *Calcif Tissue Int* 2022; **110**: 546-561 [PMID: 34236445 DOI: 10.1007/s00223-021-00885-6]

59 **Nampoothiri S**, Guillemyn B, Elcioglu N, Jagadeesh S, Yesodharan D, Suresh B, Turan S, Symoens S, Malfait F. Ptosis as a unique hallmark for autosomal recessive WNT1-associated osteogenesis imperfecta. *Am J Med Genet A* 2019; **179**: 908-914 [PMID: 30896082 DOI: 10.1002/ajmg.a.61119]

60 **Pyott SM**, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. *Am J Hum Genet* 2013; **92**: 590-597 [PMID: 23499310 DOI: 10.1016/j.ajhg.2013.02.009]

61 **Keller RB**, Tran TT, Pyott SM, Pepin MG, Savarirayan R, McGillivray G, Nickerson DA, Bamshad MJ, Byers PH. Monoallelic and biallelic CREB3L1 variant causes mild and severe osteogenesis imperfecta, respectively. *Genet Med* 2018; **20**: 411-419 [PMID: 28817112 DOI: 10.1038/gim.2017.115]

62 **Lu CL**, Ortmeier S, Brudvig J, Moretti T, Cain J, Boyadjiev SA, Weimer JM, Kim J. Collagen has a unique SEC24 preference for efficient export from the endoplasmic reticulum. *Traffic* 2022; **23**: 81-93 [PMID: 34761479 DOI: 10.1111/tra.12826]

63 **Guillemyn B**, Kayserili H, Demuynck L, Sips P, De Paepe A, Syx D, Coucke PJ, Malfait F, Symoens S. A homozygous pathogenic missense variant broadens the phenotypic and mutational spectrum of CREB3L1-related osteogenesis imperfecta. *Hum Mol Genet* 2019; **28**: 1801-1809 [PMID: 30657919 DOI: 10.1093/hmg/ddz017]

64 **Cayami FK**, Maugeri A, Treurniet S, Setijowati ED, Teunissen BP, Eekhoff EMW, Pals G, Faradz SM, Micha D. The first family with adult osteogenesis imperfecta caused by a novel homozygous mutation in CREB3L1. *Mol Genet Genomic Med* 2019; **7**: e823 [PMID: 31207160 DOI: 10.1002/mgg3.823]

65 **Lindahl K**, Åström E, Dragomir A, Symoens S, Coucke P, Larsson S, Paschalis E, Roschger P, Gamsjaeger S, Klaushofer K, Fratzl-Zelman N, Kindmark A. Homozygosity for CREB3L1 premature stop codon in first case of recessive osteogenesis imperfecta associated with OASIS-deficiency to survive infancy. *Bone* 2018; **114**: 268-277 [PMID: 29936144 DOI: 10.1016/j.bone.2018.06.019]

66 **Lima MLS**, Medeiros CACX, Guerra GCB, Santos R, Bader M, Pirih FQ, Araújo Júnior RF, Chan AB, Cruz LJ, Brito GAC, Leitão RFC, Silveira EJDD, Garcia VB, Martins AA, Araújo AA. AT1 and AT2 Receptor Knockout Changed Osteonectin and Bone Density in Mice in Periodontal Inflammation Experimental Model. *Int J Mol Sci* 2021; **22** [PMID: 34069164 DOI: 10.3390/ijms22105217]

67 **Rosset EM**, Bradshaw AD. SPARC/osteonectin in mineralized tissue. *Matrix Biol* 2016; **52-54**: 78-87 [PMID: 26851678 DOI: 10.1016/j.matbio.2016.02.001]

68 **Durkin A**, DeVile C, Arundel P, Bull M, Walsh J, Bishop NJ, Hupin E, Parekh S, Nadarajah R, Offiah AC, Calder A, Brock J, Baker D, Balasubramanian M. Expanding the phenotype of SPARC-related osteogenesis imperfecta: clinical findings in two patients with pathogenic variants in SPARC and literature review. *J Med Genet* 2022; **59**: 810-816 [PMID: 34462290 DOI: 10.1136/jmedgenet-2021-107942]

69 **Hayat A**, Hussain S, Bilal M, Kausar M, Almuzzaini B, Abbas S, Tanveer A, Khan A, Siddiqi S, Foo JN, Ahmad F, Khan F, Khan B, Anees M, Mäkitie O, Alfadhel M, Ahmad W, Umair M. Biallelic variants in four genes underlying recessive osteogenesis imperfecta. *Eur J Med Genet* 2020; **63**: 103954 [PMID: 32413570 DOI: 10.1016/j.ejmg.2020.103954]

70 **Mendoza-Londono R**, Fahiminiya S, Majewski J; Care4Rare Canada Consortium, Tétreault M, Nadaf J, Kannu P, Sochett E, Howard A, Stimec J, Dupuis L, Roschger P, Klaushofer K, Palomo T, Ouellet J, Al-Jallad H, Mort JS, Moffatt P, Boudko S, Bächinger HP, Rauch F. Recessive osteogenesis imperfecta caused by missense mutations in SPARC. *Am J Hum Genet* 2015; **96**: 979-985 [PMID: 26027498 DOI: 10.1016/j.ajhg.2015.04.021]

71 **Lin HH**, Lo YL, Wang WC, Huang KY, I KY, Chang GW. Overexpression of FAM46A, a Non-canonical Poly(A) Polymerase, Promotes Hemin-Induced Hemoglobinization in K562 Cells. *Front Cell Dev Biol* 2020; **8**: 414 [PMID: 32528962 DOI: 10.3389/fcell.2020.00414]

72 **Watanabe T**, Yamamoto T, Tsukano K, Hirano S, Horikawa A, Michiue T. Fam46a regulates BMP-dependent pre-placodal ectoderm differentiation in Xenopus. *Development* 2018; **145** [PMID: 30291163 DOI: 10.1242/dev.166710]

73 **Doyard M**, Bacrot S, Huber C, Di Rocco M, Goldenberg A, Aglan MS, Brunelle P, Temtamy S, Michot C, Otaify GA, Haudry C, Castanet M, Leroux J, Bonnefont JP, Munnich A, Baujat G, Lapunzina P, Monnot S, Ruiz-Perez VL, Cormier-Daire V. FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta. *J Med Genet* 2018; **55**: 278-284 [PMID: 29358272 DOI: 10.1136/jmedgenet-2017-104999]

74 **Caengprasath N**, Theerapanon T, Porntaveetus T, Shotelersuk V. MBTPS2, a membrane bound protease, underlying several distinct skin and bone disorders. *J Transl Med* 2021; **19**: 114 [PMID: 33743732 DOI: 10.1186/s12967-021-02779-5]

75 **Lindert U**, Cabral WA, Ausavarat S, Tongkobpetch S, Ludin K, Barnes AM, Yeetong P, Weis M, Krabichler B, Srichomthong C, Makareeva EN, Janecke AR, Leikin S, Röthlisberger B, Rohrbach M, Kennerknecht I, Eyre DR, Suphapeetiporn K, Giunta C, Marini JC, Shotelersuk V. MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. *Nat Commun* 2016; **7**: 11920 [PMID: 27380894 DOI: 10.1038/ncomms11920]

76 **Chen C**, Xu C, Li H, Jia M, Tang S. Novel mutation in MBTPS2 causes keratosis follicularis spinulosa decalvans in a large Chinese family. *Int J Dermatol* 2019; **58**: 493-496 [PMID: 29951998 DOI: 10.1111/ijd.14129]

77 **Naiki M**, Mizuno S, Yamada K, Yamada Y, Kimura R, Oshiro M, Okamoto N, Makita Y, Seishima M, Wakamatsu N. MBTPS2 mutation causes BRESEK/BRESHECK syndrome. *Am J Med Genet A* 2012; **158A**: 97-102 [PMID: 22105905 DOI: 10.1002/ajmg.a.34373]

78 **Oeffner F**, Fischer G, Happle R, König A, Betz RC, Bornholdt D, Neidel U, Boente Mdel C, Redler S, Romero-Gomez J, Salhi A, Vera-Casaño A, Weirich C, Grzeschik KH. IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for cholesterol homeostasis and ER stress response. *Am J Hum Genet* 2009; **84**: 459-467 [PMID: 19361614 DOI: 10.1016/j.ajhg.2009.03.014]

79 **Moosa S**, Yamamoto GL, Garbes L, Keupp K, Beleza-Meireles A, Moreno CA, Valadares ER, de Sousa SB, Maia S, Saraiva J, Honjo RS, Kim CA, Cabral de Menezes H, Lausch E, Lorini PV, Lamounier A Jr, Carniero TCB, Giunta C, Rohrbach M, Janner M, Semler O, Beleggia F, Li Y, Yigit G, Reintjes N, Altmüller J, Nürnberg P, Cavalcanti DP, Zabel B, Warman ML, Bertola DR, Wollnik B, Netzer C. Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta. *Am J Hum Genet* 2019; **105**: 836-843 [PMID: 31564437 DOI: 10.1016/j.ajhg.2019.08.008]

80 **Stürznickel J**, Jähn-Rickert K, Zustin J, Hennig F, Delsmann MM, Schoner K, Rehder H, Kreczy A, Schinke T, Amling M, Kornak U, Oheim R. Compound Heterozygous Frameshift Mutations in MESD Cause a Lethal Syndrome Suggestive of Osteogenesis Imperfecta Type XX. *J Bone Miner Res* 2021; **36**: 1077-1087 [PMID: 33596325 DOI: 10.1002/jbmr.4277]

81 **Efthymiou S**, Herman I, Rahman F, Anwar N, Maroofian R, Yip J, Mitani T, Calame DG, Hunter JV, Sutton VR, Yilmaz Gulec E, Duan R, Fatih JM, Marafi D, Pehlivan D, Jhangiani SN, Gibbs RA, Posey JE; SYNAPS Study Group, Maqbool S, Lupski JR, Houlden H. Two novel bi-allelic KDELR2 missense variants cause osteogenesis imperfecta with neurodevelopmental features. *Am J Med Genet A* 2021; **185**: 2241-2249 [PMID: 33964184 DOI: 10.1002/ajmg.a.62221]

82 **van Dijk FS**, Semler O, Etich J, Köhler A, Jimenez-Estrada JA, Bravenboer N, Claeys L, Riesebos E, Gegic S, Piersma SR, Jimenez CR, Waisfisz Q, Flores CL, Nevado J, Harsevoort AJ, Janus GJM, Franken AAM, van der Sar AM, Meijers-Heijboer H, Heath KE, Lapunzina P, Nikkels PGJ, Santen GWE, Nüchel J, Plomann M, Wagener R, Rehberg M, Hoyer-Kuhn H, Eekhoff EMW, Pals G, Mörgelin M, Newstead S, Wilson BT, Ruiz-Perez VL, Maugeri A, Netzer C, Zaucke F, Micha D. Interaction between KDELR2 and HSP47 as a Key Determinant in Osteogenesis Imperfecta Caused by Bi-allelic Variants in KDELR2. *Am J Hum Genet* 2020; **107**: 989-999 [PMID: 33053334 DOI: 10.1016/j.ajhg.2020.09.009]

83 **Dubail J**, Brunelle P, Baujat G, Huber C, Doyard M, Michot C, Chavassieux P, Khairouni A, Topouchian V, Monnot S, Koumakis E, Cormier-Daire V. Homozygous Loss-of-Function Mutations in CCDC134 Are Responsible for a Severe Form of Osteogenesis Imperfecta. *J Bone Miner Res* 2020; **35**: 1470-1480 [PMID: 32181939 DOI: 10.1002/jbmr.4011]

84 **Ali TM**, Linnenkamp BDW, Yamamoto GL, Honjo RS, Cabral de Menezes Filho H, Kim CA, Bertola DR. The recurrent homozygous translation start site variant in CCDC134 in an individual with severe osteogenesis imperfecta of non-Morrocan ancestry. *Am J Med Genet A* 2022; **188**: 1545-1549 [PMID: 35019224 DOI: 10.1002/ajmg.a.62651]

85 **Holick MF**, Shirvani A, Charoenngam N. Fetal Fractures in an Infant with Maternal Ehlers-Danlos Syndrome, CCDC134 Pathogenic Mutation and a Negative Genetic Test for Osteogenesis Imperfecta. *Children (Basel)* 2021; **8** [PMID: 34204301 DOI: 10.3390/children8060512]

86 **Zhytnik L**, Simm K, Salumets A, Peters M, Märtson A, Maasalu K. Reproductive options for families at risk of Osteogenesis Imperfecta: a review. *Orphanet J Rare Dis* 2020; **15**: 128 [PMID: 32460820 DOI: 10.1186/s13023-020-01404-w]

87 **Zhytnik L**, Maasalu K, Duy BH, Pashenko A, Khmyzov S, Reimann E, Prans E, Kõks S, Märtson A. De novo and inherited pathogenic variants in collagen-related osteogenesis imperfecta. *Mol Genet Genomic Med* 2019; **7**: e559 [PMID: 30675999 DOI: 10.1002/mgg3.559]

88 **Mei Y**, Zhang H, Zhang Z. Comparing Clinical and Genetic Characteristics of De Novo and Inherited COL1A1/COL1A2 Variants in a Large Chinese Cohort of Osteogenesis Imperfecta. *Front Endocrinol (Lausanne)* 2022; **13**: 935905 [PMID: 35909573 DOI: 10.3389/fendo.2022.935905]

89 **Pyott SM**, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH. Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. *Genet Med* 2011; **13**: 125-130 [PMID: 21239989 DOI: 10.1097/GIM.0b013e318202e0f6]

90 **Mathijssen IB**, van Maarle MC, Kleiss IIM, Redeker EJW, Ten Kate LP, Henneman L, Meijers-Heijboer H. With expanded carrier screening, founder populations run the risk of being overlooked. *J Community Genet* 2017; **8**: 327-333 [PMID: 28555434 DOI: 10.1007/s12687-017-0309-5]

91 **Cabral WA**, Barnes AM, Adeyemo A, Cushing K, Chitayat D, Porter FD, Panny SR, Gulamali-Majid F, Tishkoff SA, Rebbeck TR, Gueye SM, Bailey-Wilson JE, Brody LC, Rotimi CN, Marini JC. A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta. *Genet Med* 2012; **14**: 543-551 [PMID: 22281939 DOI: 10.1038/gim.2011.44]

92 **Essawi O**, Symoens S, Fannana M, Darwish M, Farraj M, Willaert A, Essawi T, Callewaert B, De Paepe A, Malfait F, Coucke PJ. Genetic analysis of osteogenesis imperfecta in the Palestinian population: molecular screening of 49 affected families. *Mol Genet Genomic Med* 2018; **6**: 15-26 [PMID: 29150909 DOI: 10.1002/mgg3.331]

93 **Schwarze U**, Cundy T, Pyott SM, Christiansen HE, Hegde MR, Bank RA, Pals G, Ankala A, Conneely K, Seaver L, Yandow SM, Raney E, Babovic-Vuksanovic D, Stoler J, Ben-Neriah Z, Segel R, Lieberman S, Siderius L, Al-Aqeel A, Hannibal M, Hudgins L, McPherson E, Clemens M, Sussman MD, Steiner RD, Mahan J, Smith R, Anyane-Yeboa K, Wynn J, Chong K, Uster T, Aftimos S, Sutton VR, Davis EC, Kim LS, Weis MA, Eyre D, Byers PH. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. *Hum Mol Genet* 2013; **22**: 1-17 [PMID: 22949511 DOI: 10.1093/hmg/dds371]

94 **Vorster A**, Beighton P, Chetty M, Ganie Y, Henderson B, Honey E, Maré P, Thompson D, Fieggen K, Viljoen D, Ramesar R. Osteogenesis imperfecta type 3 in South Africa: Causative mutations in FKBP10. *S Afr Med J* 2017; **107**: 457-462 [PMID: 28492130 DOI: 10.7196/SAMJ.2017.v107i5.9461]

95 **Zhu W**, Yan K, Chen X, Zhao W, Wu Y, Tang H, Chen M, Wu J, Wang P, Zhang R, Shen Y, Zhang D. A Founder Pathogenic Variant of PPIB Unique to Chinese Population Causes Osteogenesis Imperfecta IX. *Front Genet* 2021; **12**: 717294 [PMID: 34659339 DOI: 10.3389/fgene.2021.717294]

96 **Hu J**, Li LJ, Zheng WB, Zhao DC, Wang O, Jiang Y, Xing XP, Li M, Xia W. A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta. *Mol Genet Genomic Med* 2020; **8**: e1525 [PMID: 33166085 DOI: 10.1002/mgg3.1525]

97 **Garibaldi N**, Besio R, Dalgleish R, Villani S, Barnes AM, Marini JC, Forlino A. Dissecting the phenotypic variability of osteogenesis imperfecta. *Dis Model Mech* 2022; **15** [PMID: 35575034 DOI: 10.1242/dmm.049398]

98 **Yang L**, Liu B, Dong X, Wu J, Sun C, Xi L, Cheng R, Wu B, Wang H, Tong S, Wang D, Luo F. Clinical severity prediction in children with osteogenesis imperfecta caused by COL1A1/2 defects. *Osteoporos Int* 2022; **33**: 1373-1384 [PMID: 35044492 DOI: 10.1007/s00198-021-06263-0]

99 **Zhang J**, Lai Z, Shi L, Tian Y, Luo A, Xu Z, Ma X, Wang S. Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice. *Aging (Albany NY)* 2018; **10**: 1089-1102 [PMID: 29787998 DOI: 10.18632/aging.101449]

100 **De Rycke M**, Berckmoes V. Preimplantation Genetic Testing for Monogenic Disorders. *Genes (Basel)* 2020; **11** [PMID: 32752000 DOI: 10.3390/genes11080871]

101 **Zanetti BF**, Braga DPAF, Azevedo MC, Setti AS, Figueira RCS, Iaconelli A Jr, Borges E Jr. Preimplantation genetic testing for monogenic diseases: a Brazilian IVF centre experience. *JBRA Assist Reprod* 2019; **23**: 99-105 [PMID: 30614237 DOI: 10.5935/1518-0557.20180076]

102 **Bonanni G**, Trevisan V, Zollino M, De Santis M, Romanzi F, Lanzone A, Bevilacqua E. Case Report: Challenges of Non-Invasive Prenatal Testing (NIPT): A Case Report of Confined Placental Mosaicism and Clinical Considerations. *Front Genet* 2022; **13**: 881284 [PMID: 35646091 DOI: 10.3389/fgene.2022.881284]

103 **Gorduza EV**, Popescu R, Caba L, Ivanov I, Martiniuc V, Nedelea F, Militaru M, Socolov DG. Prenatal diagnosis of 21 trisomy by quantification of methylated fetal DNA in maternal blood: study on 10 pregnancies. *Rev Rom Med Lab* 2013; **21**: 275–284 [DOI: 10.2478/rrlm-2013-0030]

104 **Gug C**, Mozos I, Ratiu A, Tudor A, Gorduza EV, Caba L, Gug M, Cojocariu C, Furau C, Furau G, Vaida MA, Stoicanescu D. Genetic Counseling and Management: The First Study to Report NIPT Findings in a Romanian Population. *Medicina (Kaunas)* 2022; **58** [PMID: 35056387 DOI: 10.3390/medicina58010079]

105 **Liehr T**. False-positives and false-negatives in non-invasive prenatal testing (NIPT): what can we learn from a meta-analyses on > 750,000 tests? *Mol Cytogenet* 2022; **15**: 36 [PMID: 35986330 DOI: 10.1186/s13039-022-00612-2]

106 **Shaw J**, Scotchman E, Chandler N, Chitty LS. PREIMPLANTATION GENETIC TESTING: Non-invasive prenatal testing for aneuploidy, copy-number variants and single-gene disorders. *Reproduction* 2020; **160**: A1-A11 [PMID: 32130205 DOI: 10.1530/REP-19-0591]

107 **Deguchi M**, Tsuji S, Katsura D, Kasahara K, Kimura F, Murakami T. Current Overview of Osteogenesis Imperfecta. *Medicina (Kaunas)* 2021; **57** [PMID: 34068551 DOI: 10.3390/medicina57050464]

108 **Gug C**, Caba L, Mozos I, Stoian D, Atasie D, Gug M, Gorduza EV. Rare splicing mutation in COL1A1 gene identified by whole exomes sequencing in a patient with osteogenesis imperfecta type I followed by prenatal diagnosis: A case report and review of the literature. *Gene* 2020; **741**: 144565 [PMID: 32165296 DOI: 10.1016/j.gene.2020.144565]

109 **Milks KS**, Hill LM, Hosseinzadeh K. Evaluating skeletal dysplasias on prenatal ultrasound: an emphasis on predicting lethality. *Pediatr Radiol* 2017; **47**: 134-145 [PMID: 27904917 DOI: 10.1007/s00247-016-3725-5]

110 **Gilligan LA**, Calvo-Garcia MA, Weaver KN, Kline-Fath BM. Fetal magnetic resonance imaging of skeletal dysplasias. *Pediatr Radiol* 2020; **50**: 224-233 [PMID: 31776601 DOI: 10.1007/s00247-019-04537-8]

111 **Nelson DB**, Dashe JS, McIntire DD, Twickler DM. Fetal skeletal dysplasias: sonographic indices associated with adverse outcomes. *J Ultrasound Med* 2014; **33**: 1085-1090 [PMID: 24866616 DOI: 10.7863/ultra.33.6.1085]

112 **Waratani M**, Ito F, Tanaka Y, Mabuchi A, Mori T, Kitawaki J. Prenatal diagnosis of fetal skeletal dysplasia using 3-dimensional computed tomography: a prospective study. *BMC Musculoskelet Disord* 2020; **21**: 662 [PMID: 33032557 DOI: 10.1186/s12891-020-03663-x]

113 **Bellur S**, Jain M, Cuthbertson D, Krakow D, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Krischer J, Mullins M, Byers PH, Pepin M, Durigova M, Glorieux FH, Rauch F, Sutton VR, Lee B; Members of the BBD Consortium, Nagamani SC. Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. *Genet Med* 2016; **18**: 570-576 [PMID: 26426884 DOI: 10.1038/gim.2015.131]

114 **Chamunyonga F**, Masendeke KL, Mateveke B. Osteogenesis imperfecta and pregnancy: a case report. *J Med Case Rep* 2019; **13**: 363 [PMID: 31822291 DOI: 10.1186/s13256-019-2296-0]

115 **Cozzolino M**, Perelli F, Maggio L, Coccia ME, Quaranta M, Gizzo S, Mecacci F. Management of osteogenesis imperfecta type I in pregnancy; a review of literature applied to clinical practice. *Arch Gynecol Obstet* 2016; **293**: 1153-1159 [PMID: 26781260 DOI: 10.1007/s00404-016-4012-2]

116 **Ralston SH**, Gaston MS. Management of Osteogenesis Imperfecta. *Front Endocrinol (Lausanne)* 2019; **10**: 924 [PMID: 32117044 DOI: 10.3389/fendo.2019.00924]

117 **Folkestad L**, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. *J Bone Miner Res* 2016; **31**: 2159-2166 [PMID: 27345018 DOI: 10.1002/jbmr.2895]

118 **Balasubramanian M**, Verschueren A, Kleevens S, Luyckx I, Perik M, Schirwani S, Mortier G, Morisaki H, Rodrigus I, Van Laer L, Verstraeten A, Loeys B. Aortic aneurysm/dissection and osteogenesis imperfecta: Four new families and review of the literature. *Bone* 2019; **121**: 191-195 [PMID: 30684648 DOI: 10.1016/j.bone.2019.01.022]

119 **Jensen PR**, Andersen TL, Chavassieux P, Roux JP, Delaisse JM. Bisphosphonates impair the onset of bone formation at remodeling sites. *Bone* 2021; **145**: 115850 [PMID: 33465485 DOI: 10.1016/j.bone.2021.115850]

120 **Bains JS**, Carter EM, Citron KP, Boskey AL, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Cuthbertson D, Krischer J, Byers PH, Pepin M, Durigova M, Glorieux FH, Rauch F, Sliepka JM, Sutton VR, Lee B; Members of the BBD Consortium, Nagamani SC, Raggio CL. A Multicenter Observational Cohort Study to Evaluate the Effects of Bisphosphonate Exposure on Bone Mineral Density and Other Health Outcomes in Osteogenesis Imperfecta. *JBMR Plus* 2019; **3**: e10118 [PMID: 31131341 DOI: 10.1002/jbm4.10118]

121 **Bradbury LA**, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. *Osteoporos Int* 2012; **23**: 285-294 [PMID: 21739105 DOI: 10.1007/s00198-011-1658-2]

122 **Dwan K**, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. *Cochrane Database Syst Rev* 2016; **10**: CD005088 [PMID: 27760454 DOI: 10.1002/14651858.CD005088.pub4]

123 **Ying ZM**, Hu B, Yan SG. Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials. *Orthop Surg* 2020; **12**: 1293-1303 [PMID: 32589343 DOI: 10.1111/os.12611]

124 **Ma S**, Goh EL, Jin A, Bhattacharya R, Boughton OR, Patel B, Karunaratne A, Vo NT, Atwood R, Cobb JP, Hansen U, Abel RL. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. *Sci Rep* 2017; **7**: 43399 [PMID: 28262693 DOI: 10.1038/srep43399]

125 **Green SB**, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. *Am J Health Syst Pharm* 2014; **71**: 2029-2036 [PMID: 25404594 DOI: 10.2146/ajhp140041]

126 **Botor M**, Fus-Kujawa A, Uroczynska M, Stepien KL, Galicka A, Gawron K, Sieron AL. Osteogenesis Imperfecta: Current and Prospective Therapies. *Biomolecules* 2021; **11** [PMID: 34680126 DOI: 10.3390/biom11101493]

127 **Hoyer-Kuhn H**, Rehberg M, Netzer C, Schoenau E, Semler O. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort. *Orphanet J Rare Dis* 2019; **14**: 219 [PMID: 31533771 DOI: 10.1186/s13023-019-1197-z]

128 **Lee LR**, Holman AE, Li X, Vasiljevski ER, O'Donohue AK, Cheng TL, Little DG, Schindeler A, Biggin A, Munns CF. Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta. *Bone* 2022; **159**: 116378 [PMID: 35257929 DOI: 10.1016/j.bone.2022.116378]

129 **Rossi V**, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. *Curr Opin Pediatr* 2019; **31**: 708-715 [PMID: 31693577 DOI: 10.1097/MOP.0000000000000813]

130 **Orwoll ES**, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. *J Clin Invest* 2014; **124**: 491-498 [PMID: 24463451 DOI: 10.1172/JCI71101]

131 **Vahle JL**, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. *Toxicol Pathol* 2002; **30**: 312-321 [PMID: 12051548 DOI: 10.1080/01926230252929882]

132 **Glorieux FH**, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, Junker U, Ruckle J, Seefried L, Winkle PJ. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. *J Bone Miner Res* 2017; **32**: 1496-1504 [PMID: 28370407 DOI: 10.1002/jbmr.3143]

133 **Uehara M**, Nakamura Y, Nakano M, Miyazaki A, Suzuki T, Takahashi J. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report. *Mod Rheumatol Case Rep* 2022; **6**: 128-133 [PMID: 34491363 DOI: 10.1093/mrcr/rxab018]

134 **Lv F**, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. *Bone* 2020; **130**: 115121 [PMID: 31678488 DOI: 10.1016/j.bone.2019.115121]

135 **Song IW**, Nagamani SC, Nguyen D, Grafe I, Sutton VR, Gannon FH, Munivez E, Jiang MM, Tran A, Wallace M, Esposito P, Musaad S, Strudthoff E, McGuire S, Thornton M, Shenava V, Rosenfeld S, Huang S, Shypailo R, Orwoll E, Lee B. Targeting TGF-β for treatment of osteogenesis imperfecta. *J Clin Invest* 2022; **132** [PMID: 35113812 DOI: 10.1172/JCI152571]

136 **Chen S**, Grover M, Sibai T, Black J, Rianon N, Rajagopal A, Munivez E, Bertin T, Dawson B, Chen Y, Jiang MM, Lee B, Yang T, Bae Y. Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton. *Mol Genet Metab* 2015; **115**: 53-60 [PMID: 25779879 DOI: 10.1016/j.ymgme.2015.02.006]

137 **Götherström C**, David AL, Walther-Jallow L, Åström E, Westgren M. Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta. *Clin Obstet Gynecol* 2021; **64**: 898-903 [PMID: 34510048 DOI: 10.1097/GRF.0000000000000656]

138 **Horwitz EM**, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. *Proc Natl Acad Sci U S A* 2002; **99**: 8932-8937 [PMID: 12084934 DOI: 10.1073/pnas.132252399]

139 **Schindeler A**, Lee LR, O'Donohue AK, Ginn SL, Munns CF. Curative Cell and Gene Therapy for Osteogenesis Imperfecta. *J Bone Miner Res* 2022; **37**: 826-836 [PMID: 35306687 DOI: 10.1002/jbmr.4549]

140 **Jung H**, Rim YA, Park N, Nam Y, Ju JH. Restoration of Osteogenesis by CRISPR/Cas9 Genome Editing of the Mutated COL1A1 Gene in Osteogenesis Imperfecta. *J Clin Med* 2021; **10** [PMID: 34300306 DOI: 10.3390/jcm10143141]

141 **Duran I**, Zieba J, Csukasi F, Martin JH, Wachtell D, Barad M, Dawson B, Fafilek B, Jacobsen CM, Ambrose CG, Cohn DH, Krejci P, Lee BH, Krakow D. 4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta. *J Bone Miner Res* 2022; **37**: 675-686 [PMID: 34997935 DOI: 10.1002/jbmr.4501]

142 **Scheiber AL**, Wilkinson KJ, Suzuki A, Enomoto-Iwamoto M, Kaito T, Cheah KS, Iwamoto M, Leikin S, Otsuru S. 4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts. *JCI Insight* 2022; **7** [PMID: 34990412 DOI: 10.1172/jci.insight.149636]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 28, 2023

**First decision:** March 10, 2023

**Article in press:** March 27, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Romania

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Muthu S, India; Stogov MV, Russia **S-Editor:** Liu XF **L-Editor:** A **P-Editor:** Yu HG

**Figure Legends**



**Figure 1** **Clinical Osteogenesis imperfecta classification (severity).** OI type I – mild form with blue sclerae, hearing loss; OI type IV – mild to moderate form with normal sclerae; OI type III - progressively deforming; OI type II – extremely severe form, lethal perinatal outcome with radiographically broad, crumpled femora and beaded ribs (Created with BioRender.com). OI: Osteogenesis imperfecta.

**Table 1 Genes and proteins in osteogenesis imperfecta[1,2,8,13,17-19]**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **OI type** | **OMIM** | **Gene symbol** | **Approved gene name** | **Location** | **Protein name** | **Functional group** |
| I | 166200 | *COL1A1* | Collagen type I alpha 1 chain | 17q21.33 | Collagen alpha-1(I) chain | A |
| II | 166210 | *COL1A1* | Collagen type I alpha 1 chain | 17q21.33 | Collagen alpha-1(I) chain | A |
| *COL1A2* | Collagen type I alpha 2 chain | 7q21.3 | Collagen alpha-2(I) chain |
| III | 259420 | *COL1A1* | Collagen type I alpha 1 chain | 17q21.33 | Collagen alpha-1(I) chain | A |
| *COL1A2* | Collagen type I alpha 2 chain | 7q21.3 | Collagen alpha-2(I) chain |
| IV | 166220 | *COL1A1* | Collagen type I alpha 1 chain | 17q21.33 | Collagen alpha-1(I) chain | A |
| *COL1A2* | Collagen type I alpha 2 chain | 7q21.3 | Collagen alpha-2(I) chain |
| V | 610967 | *IFITM5* | Interferon induced transmembrane protein 5 | 11p15.5 | Interferon-induced transmembrane protein 5 | D |
| VI | 613982 | *SERPINF1* | Serpin family F member 1 | 17p13.3 | Pigment epithelium-derived factor | D |
| VII | 610682 | *CRTAP* | Cartilage associated protein | 3p22.3 | Cartilage-associated protein | B |
| VIII | 610915 | *P3H1* | Prolyl 3-hydroxylase 1 | 1p34.2 | Prolyl 3-hydroxylase 1 | B |
| IX | 259440 | *PPIB* | Peptidylprolyl isomerase B | 15q22.31 | Peptidyl-prolyl cis-trans isomerase B | B |
| X | 613848 | *SERPINH1* | Serpin family H member 1 | 11q13.5 | Serpin H1 | C |
| XI | 610968 | *FKBP10* | FKBP prolyl isomerase 10 | 17q21.2 | Peptidyl-prolyl cis-trans isomerase *FKBP10* | C |
| XII | 613849 | *SP7* | Sp7 transcription factor | 12q13.13 | Transcription factor Sp7 | E |
| XIII | 614856 | *BMP1* | Bone morphogenetic protein 1 | 8p21.3 | Bone morphogenetic protein 1 | A |
| XIV | 615066 | *TMEM38B* | Transmembrane protein 38B | 9q31.2 | Trimeric intracellular cation channel type B | B |
| XV | 615220 | *WNT1* | Wnt family member 1 | 12q13.12 | Proto-oncogene Wnt-1 | E |
| XVI | 616229 | *CREB3L1* | cAMP responsive element binding protein 3 like 1 | 11p11.2 | Cyclic AMP-responsive element-binding protein 3-like protein 1 | E |
| XVII | 616507 | *SPARC* | Secreted protein acidic and cysteine rich | 5q33.1 | *SPARC* | E |
| XVIII | 617952 | *TENT5A* | Terminal nucleotidyltransferase 5A | 6q14.1 | Terminal nucleotidyltransferase 5A | Unclassified |
| XIX | 301014 | *MBTPS2* | Membrane bound transcription factor peptidase, site 2 | Xp22.12 | Membrane-bound transcription factor site-2 protease | E |
| XX | 618644 | *MESD* | Mesoderm development LRP chaperone | 15q25.1 | LRP chaperone MESD | Unclassified |
| XXI | 619131 | *KDELR2* | KDEL ER protein retention receptor 2 | 7p22.1 | ER lumen protein-retaining receptor 2 | C |
| XXII | 619795 | *CCDC134* | Coiled-coil domain containing 134 | 22q13.2 | Coiled-coil domain-containing protein 134 | Unclassified |

OI: Osteogenesis imperfecta; OMIM: Online Mendelian Inheritance in Man; ER: Endoplasmic reticulum; LRP: Lipoprotein receptor-related protein.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**